A pragmatic, multicenter, national, phase III, single-blinded, randomized, comparative, non-inferiority trial (11), ASPIC, explores antimicrobial stewardship strategies for ventilator-associated pneumonia in intensive care units. Five hundred and ninety adult patients, hospitalized within 24 French intensive care units, diagnosed with a first, microbiologically confirmed case of ventilator-associated pneumonia (VAP) and treated with appropriate empirical antibiotics, will be included in the study group. Randomized allocation will determine whether patients receive standard management with a 7-day antibiotic regimen, adhering to international guidelines, or antimicrobial stewardship, adapting to daily clinical cure evaluations. Clinical cure assessments will be repeated daily until a minimum of three criteria are satisfied, leading to the termination of antibiotic treatment in the experimental group. The study's key metric—a composite endpoint—includes all-cause mortality by day 28, treatment failure, and new instances of microbiologically confirmed ventilator-associated pneumonia (VAP) within 28 days.
The study protocol for the ASPIC trial (version ASPIC-13, 03 September 2021) gained approval from the French regulatory body, ANSM (EUDRACT number 2021-002197-78; 19 August 2021) and the independent ethics committee, Comite de Protection des Personnes Ile-de-France III (CNRIPH 2103.2560729; 10 October 2021), for all study sites. Participant enrollment activities are foreseen to commence in 2022. International peer-reviewed medical journals will serve as the venue for publication of the results.
NCT05124977, a unique identifier for a research study.
NCT05124977.
Reducing the impact of sarcopenia through early prevention is an advisable approach to minimize illness, mortality, and enhance quality of life. Community-dwelling older adults' risk of sarcopenia may be decreased through the application of several non-pharmacological interventions. Brain Delivery and Biodistribution Thus, establishing the domain and deviations of these interventions is imperative. Bromodeoxyuridine nmr The scope and nature of non-pharmacological interventions for community-dwelling elderly individuals potentially experiencing sarcopenia will be outlined in this comprehensive scoping review of the existing literature.
We will apply the seven-stage review methodology framework. Investigations will be conducted across Embase, Medline, PsycINFO, CINAHL, All EBM Reviews, Web of Science, Scopus, CBM, CNKI, WANFANG, and VIP databases. Grey literature discovery will also involve research on Google Scholar. Within the timeframe spanning January 2010 to December 2022, only English and Chinese language searches are available. The screening process will prioritize published research, including quantitative and qualitative study designs, alongside prospectively registered trials. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews will be adhered to when defining the search strategy. Findings will be categorized by key conceptual groupings, with quantitative and qualitative analyses employed as necessary. To determine if identified studies have been incorporated into systematic reviews or meta-analyses, and to identify and comprehensively summarize any research gaps and opportunities.
Given that this is a review, obtaining ethical approval is not necessary. The findings, which will be published in peer-reviewed scientific journals, will also be disseminated among relevant disease support groups and conferences. In order to devise a future research agenda, the planned scoping review will ascertain the current research status and any existing literature deficiencies.
Since this is a review, there is no need for ethical approval. Results will be made available through both peer-reviewed scientific journals and relevant disease support groups and conferences. To ascertain the present state of research and any gaps in the existing body of literature, a planned scoping review will be undertaken, with the aim of developing a future research agenda.
To assess the impact of cultural attendance on the risk of death from all causes.
A 36-year longitudinal cohort study (1982-2017), monitored exposure to cultural attendance at three points separated by eight-year intervals (1982/1983, 1990/1991, 1998/1999) and included a follow-up period up to December 31, 2017.
Sweden.
Among the Swedish populace, 3311 randomly selected individuals were included in the study, possessing full data for each of the three measurements.
The connection between cultural engagement levels and mortality from all causes observed during the study period. Cox proportional hazards models, incorporating time-varying covariates, were employed to estimate hazard ratios, adjusting for potential confounding factors.
Compared to the highest level of cultural attendance (reference; HR=1), the lowest and middle levels exhibited hazard ratios of 163 (95% confidence interval 134-200) and 125 (95% confidence interval 103-151), respectively.
There exists a gradient in attendance at cultural events; the degree of exposure negatively correlates with all-cause mortality during the observation period.
A gradient exists in the participation of cultural events, such that limited cultural experiences are linked to a higher risk of all-cause mortality during the follow-up period.
Analyzing the rate of long COVID symptoms in children, separated based on SARS-CoV-2 infection history, and identifying factors contributing to the persistence of long COVID is the research goal.
A nationwide, cross-sectional survey.
Primary care is a crucial aspect of healthcare.
A survey about SARS-CoV-2 infection completed by 3240 parents of children aged 5-18, a response rate exceeding 100% at 119%, revealed unique insights. The parents were categorized based on their prior infection history: 1148 had no prior infection, and 2092 had a history of SARS-CoV-2 infection.
Prevalence of long COVID symptoms among children with or without a history of infection served as the primary endpoint. Factors associated with long COVID symptoms and the failure of children previously infected to return to baseline health were investigated as secondary outcomes, focusing on variables like gender, age, time elapsed from the initial illness, symptomatic presentation, and vaccination history.
Headaches (211 [184%] vs 114 [54%], p<0.0001), weakness (173 [151%] vs 70 [33%], p<0.0001), fatigue (141 [123%] vs 133 [64%], p<0.0001), and abdominal pain (109 [95%] vs 79 [38%], p<0.0001) were more frequently reported in children with a history of SARS-CoV-2 infection experiencing long COVID symptoms. parenteral immunization The 12-18 year old age group of children with a past SARS-CoV-2 infection reported a higher frequency of long COVID symptoms, compared to the 5-11 age group. Children not previously infected with SARS-CoV-2 exhibited more frequent symptoms, including attention problems leading to school difficulties (225 (108%) vs 98 (85%), p=0.005), stress (190 (91%) vs 65 (57%), p<0.0001), social issues (164 (78%) vs 32 (28%)), and changes in weight (143 (68%) vs 43 (37%), p<0.0001).
This study implies that the prevalence of long COVID symptoms in adolescents with prior SARS-CoV-2 infection could surpass that observed in young children, highlighting a potential disparity. The increased prevalence of somatic symptoms, particularly in children with no prior SARS-CoV-2 infection, underscored the pandemic's influence apart from the direct infection.
Adolescents, having previously been infected with SARS-CoV-2, may demonstrate a higher and more prevalent manifestation of long COVID symptoms, as per this study, compared to young children. Children without previous SARS-CoV-2 infection presented with a more pronounced occurrence of somatic symptoms, emphasizing the broader influence of the pandemic.
Cancer-related neuropathic pain frequently afflicts patients, leaving them without relief. The psychoactive side effects frequently observed in modern analgesic treatments, coupled with a lack of efficacy data and the potential for medication-related harm, are significant concerns. Lidocaine (lignocaine), delivered via a continuous and prolonged subcutaneous infusion, shows promise in managing chronic cancer-related neuropathic pain. The data on lidocaine in this setting highlight its promising safety profile and efficacy, calling for further evaluation through rigorous, randomized, controlled trials. This protocol details a pilot study's design for evaluating this intervention, leveraging pharmacokinetic, efficacy, and adverse effect data to inform the plan.
A pilot study combining qualitative and quantitative methods will assess the feasibility of a world-leading, international Phase III trial, designed to evaluate the efficacy and safety of extended continuous subcutaneous lidocaine infusions for patients experiencing neuropathic cancer pain. In a phase II, double-blind, randomized, controlled, parallel-group pilot study, subcutaneous infusions of lidocaine hydrochloride 10%w/v (3000 mg/30 mL) over 72 hours will be compared to placebo (sodium chloride 0.9%) for the treatment of neuropathic cancer pain. This includes a pharmacokinetic sub-study and a qualitative sub-study of patient and caregiver perspectives. By collecting pivotal safety data, the pilot study will inform the methodology of a definitive trial, evaluating the proposed recruitment strategy, randomization process, outcome measures, and patient acceptability, while signaling the need for further research in this area.
The trial protocol is structured to guarantee participant safety, with standardized assessments of adverse effects an integral component. The findings, subject to peer review, will be disseminated through journal publications and conference presentations. Progressing to a phase III study hinges on a completion rate within the confidence interval, encompassing 80% and excluding 60%. The protocol, as well as the Patient Information and Consent Form, are now approved by the Sydney Local Health District (Concord) Human Research Ethics Committee, reference number 2019/ETH07984, and the University of Technology Sydney Ethics Committee, ETH17-1820.